Volta Medical presents results from the first transatlantic randomized controlled trial comparing AI-assisted ablation procedure with the conventional treatment for persistent atrial fibrillation patients
May 20, 2024 08:00 ET
|
Volta Medical
TAILORED-AF trial findings demonstrated superiority in freedom from atrial fibrillation (AF) with or without anti-arrhythmic drugs at 12 months from a tailored cardiac ablation guided by artificial...
Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation
May 09, 2024 08:00 ET
|
Volta Medical
Published in the EP Europace Journal, the consensus statement highlights Volta’s AI Companion and the TAILORED-AF clinical trial. MARSEILLE, France, May 09, 2024 (GLOBE NEWSWIRE) -- Volta Medical,...
Volta Medical Announces Presentations at Heart Rhythm Society 2024 in Boston, MA, USA
April 18, 2024 08:00 ET
|
Volta Medical
• Demonstration of Volta AF-Xplorer™ at Heart Rhythm Society (HRS) 2024, May 16-19• Dr. Andrea Natale, a world recognized leader in the field of electrophysiology, to moderate Rhythm Theater ...
Volta Medical Receives CE Mark for AF-Xplorer™ Decision support solution to Simplify Complex Atrial Fibrillation Procedures
February 28, 2024 08:00 ET
|
Volta Medical
Proprietary AI companion technology assists electrophysiologists by reducing ambiguity in mapped atrial fibrillation (AF) patterns MARSEILLE, France, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Volta...
Volta Medical Named Best Startup at Prix Galien USA Awards 2023
November 02, 2023 08:00 ET
|
Volta Medical
MARSEILLE, France, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians...
Volta Medical Announces Initiation of RESTART Clinical Trial for Treatment of Repeat Atrial Fibrillation
June 22, 2023 08:00 ET
|
Volta Medical
Interventional study to evaluate long term outcomes of Volta’s AI solution-supported ablation in recurrent-AF patients who failed previous ablationInternational, multi-center trial at 21 sites with...
Volta Medical Announces FDA Clearance of Volta AF-Xplorer™ Software to Simplify Complex Atrial Fibrillation Procedures
May 18, 2023 17:00 ET
|
Volta Medical
• Live demonstration of new software at Heart Rhythm Society (HRS) 2023, May 19-21 MARSEILLE, France, May 18, 2023 (GLOBE NEWSWIRE) -- Volta Medical, a pioneering health technology company...
Volta Medical Announces Completion of Patient Enrollment in TAILORED-AF Clinical Trial for Treatment of Atrial Fibrillation
February 02, 2023 08:00 ET
|
Volta Medical
• First randomized controlled clinical trial to evaluate VX1-guided ablation compared to conventional anatomical ablation approaches to treat persistent atrial fibrillation• International,...
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
January 05, 2023 08:00 ET
|
Volta Medical
New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence (AI) Decision-Support Software in improving...
Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication
August 31, 2022 08:00 ET
|
Volta Medical
Volta VX1 decision support software reproduces expert-physician electrogram (EGM) analysis that can assist physicians in the real-time identification of specific abnormal electrograms in a persistent...